2019
Proinsulin Expressing Neuroendocrine Tumors of the Pancreas
Celli R, Tang LH, Cai G, Freedman-Weiss M, Colunga M, Salem RR, Majumdar S, Jain D. Proinsulin Expressing Neuroendocrine Tumors of the Pancreas. Pancreas 2019, 48: 55-59. PMID: 30451800, DOI: 10.1097/mpa.0000000000001196.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdultAgedBiomarkers, TumorBlood GlucoseFemaleHumansHypoglycemiaInsulinInsulinomaMaleMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsProinsulinConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsAvailable clinicopathologic dataIHC-negative tumorsSurgical oncology centersNormal insulin levelsIHC-positive tumorsSerum proinsulinClinicopathologic featuresPNET patientsClinicopathologic dataHypoglycemic patientsInsulin levelsProspective studyOncology centersSerum glucoseSuch tumorsClinical significanceInsulin immunohistochemistryRare casePatientsImmunohistochemistryProinsulinomaTumorsInsulinoma
2017
A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors
Murtha TD, Lupsa BC, Majumdar S, Jain D, Salem RR. A Systematic Review of Proinsulin-Secreting Pancreatic Neuroendocrine Tumors. Journal Of Gastrointestinal Surgery 2017, 21: 1335-1341. PMID: 28510792, DOI: 10.1007/s11605-017-3428-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAgedBiomarkers, TumorFemaleHumansInsulinomaMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsProinsulinConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsSystematic reviewRare pancreatic neuroendocrine tumorYale-New Haven HospitalMajority of patientsMedian tumor diameterLower insulin levelsBiomedical databases PubMedNew Haven HospitalSymptomatic hypoglycemiaMost patientsFemale predominanceTumor diameterClinicopathologic featuresInsulin levelsUncommon diseaseMean ageOvid MEDLINEHormonal levelsDatabases PubMedPatientsProinsulinomaHormone productionTumors
2012
PDX-1, CDX-2, TTF-1, and CK7
Chan ES, Alexander J, Swanson PE, Jain D, Yeh MM. PDX-1, CDX-2, TTF-1, and CK7. The American Journal Of Surgical Pathology 2012, 36: 737-743. PMID: 22498824, DOI: 10.1097/pas.0b013e31824aba59.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCDX2 Transcription FactorDiagnosis, DifferentialDNA-Binding ProteinsFemaleHomeodomain ProteinsHumansImmunohistochemistryIntestinal NeoplasmsKeratin-20Keratin-7Liver NeoplasmsLung NeoplasmsMaleMiddle AgedNeuroendocrine TumorsPancreatic NeoplasmsSensitivity and SpecificitySingle-Blind MethodTrans-ActivatorsTranscription FactorsConceptsGI neuroendocrine tumorsThyroid transcription factor-1Pancreatic neuroendocrine tumorsBronchopulmonary neuroendocrine tumorsMetastatic neuroendocrine tumorsPrimary neuroendocrine tumorNeuroendocrine tumorsCDX-2PDX-1Primary siteMetastatic pancreatic neuroendocrine tumorsPrimary pancreatic neuroendocrine tumorsDuodenal neuroendocrine tumorsΒ-cell functionSimilar morphologic featuresPancreatic duodenal homeobox-1Good overall diagnostic accuracyOverall diagnostic accuracyDuodenal homeobox 1Radiologic dataTranscription factor 1IHC panelImmunohistochemical markersIHC analysisKeratin 7